This page contains a Flash digital edition of a book.
Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease


35. Remels AH, Gosker HR, van der Velden J, et al., Systemic inflammation and skeletal muscle dysfunction in COPD: state of the art and novel insights in regulation of muscle plasticity, Clin Chest Med, 2007;28:(3)537–52.


36. MacNee W, Update in chronic obstructive pulmonary disease 2007, Am J Respir Crit Care Med, 2008;177(8):820–9.


37. Maclay JD, McAllister DA, MacNee W, Cardiovascular risk in chronic obstructive pulmonary disease, Respirology, 2007;12(5):634–41.


38. Gan WQ, Man SF, Senthilselvan A, Sin DD, Association between chronic obstructive pulmonary disease and systemic inflammation: a systemic review and a meta-analysis, Thorax, 2004;59(7):574–80.


39. Gaillat J, Should patients with chronic obstructive pulmonary disease be vaccinated against pneumococcal diseases?, Expert Rev Respir Med, 2009;3(6):585–96.


40. Poole PJ, Chacko E, Wood-Baker RW, Cates CJ, Influenza vaccine for patients with chronic obstructive pulmonary disease, Cochrane Database Syst Rev, 2006;25(1):CD002733.


41. Anthonisen NR, Connett JE , Murray RP, Smoking and lung function of Lung Health Study participants after 11 years, Am J Respir Crit Care Med, 2002;166(5):675–9.


42. Anthonisen NR, Connett JE, Kiley JP, et al., Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study, JAMA, 1994;272(19):1497–505.


43. US Department of Health and Human Services, The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General, Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, Co-ordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2006.


44. Fiore MC, US public health service clinical practice guide: treating tobacco use and dependence, Respir Care 2000;45(10):1200–6


45. Combivent Inhalation Aerosol Study Group, In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial, Chest, 1994;105(5):1411–9.


46. Ram FS, Sestini P, Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis, Thorax, 2003;58:(7)580–4.


47. Lee TA, Wilke C, Joo M, et al., Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease, Arch Intern Med, 2009;169(15):1403–10.


48. Tashkin DP, Celli B, Senn S, et al., A 4-year trial of tiotropium in chronic obstructive pulmonary disease, N Engl J Med, 2008;359(15):1543–54.


49. Donohue JF, van Noord JA, Bateman ED, et al., A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with


tiotropium or salmeterol, Chest, 2002;122(1):47–55.


50. Niewoehner DE, Rice K, Cote C, et al., Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial, Ann Intern Med, 2005;143(5):317–26.


51. Guell R, Casan P, Belda J, et al., Long-term effects of outpatient rehabilitation of COPD: a randomized trial, Chest, 2000;117(4):976–83.


52. Culpitt SV, Maziak W, Loukidis S, et al., Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 1999;160(5 Pt 1):1635–9.


53. Adcock IM, Barnes PJ, Molecular mechanisms of corticosteroids resistance, Chest, 2008;134(2):394–401.


54. Singh S, Loke YK, An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease, Int J Chron Obstruct Pulmon Dis, 2010;5: 189–95.


55. Burge PS, Calverley PM, Jones PW, et al., Randomized double blind placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial, Br Med J, 2000;320(7245):1297–303.


56. Welsh EJ, Cates CJ, Poole P, Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease, Cochrane Database Syst Rev, 2010;12(5):CD007891.


57. Rabe KF, Timmer W, Sagkriotis A, Viel K, Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD, Chest, 2008;134(2): 255–62.


58. Kardos P, Wencker M, Glaab T, Vogelmeier C, Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 2007;175(2):144–9.


59. Nannini LJ, Cates CJ, Lasserson TJ, Poole P, Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease, Cochrane Database Syst Rev, 2007;17(4);CD006826.


60. Welte T, Miravitlles M, Hernandez P, et al., Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 2009;180(8):741–50.


61. Calverley PM, Anderson JA, Celli B, et al., Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease, N Engl J Med, 2007;356(8):775–89.


62. Ford PA, Durham AL, Russell RE, et al., Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD, Chest, 2010;137(6):1338–44.


63. Spina D, PDE4 inhibitors: current status, Br J Pharmacol, 2008;155(3):308–15.


64. Petty TL, McCoy RW, Doherty DE, Long-term Oxygen Therapy (LTOT)—History, Scientific Foundations, and Emerging Technologies; 6th Oxygen Consensus Conference


Recommendations; National Lung Health Education Program, 2010. Available at: www.nlhep.org/pdfs/ lt_oxygen.pdf (accessed November 29, 2010).


65. National Emphysema Treatment Trial Research Group, Patients at high risk of death after lung-volume-reduction surgery, N Engl J Med, 2001;345(15):1075–83.


66. Dean MM, End-of-life care for COPD patients, Prim Care Respir J, 2008;17(1):46–50.


67. Ambrosino N, Vagheggini G, Non-invasive ventilation in exacerbations of COPD, Int J Chron Obstruct Pulmon Dis, 2007;2(4):471–6.


68. Snow V, Lascher S, Mottur-Pilson C, et al., Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease, Ann Intern Med, 2001;134(7):595–9.


69. Rothberg MB, Pekow PS, Lahti M, et al., Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease, JAMA, 2010;303(20):2035–42.


70. Stoller JK, Clinical practice. Acute exacerbations of chronic obstructive pulmonary disease, N Engl J Med, 2002;346(13): 988–94.


71. Lindsay DA, Read J, Pulmonary vascular responsiveness in the prognosis of chronic obstructive lung disease, Am Rev Respir Dis, 1972;105(2):242–50.


72. Traver GA, Cline MG, Burrows B, Predictors of mortality in chronic obstructive pulmonary disease: A 15-year follow up study, Am Rev Resp Dis, 1979;119(6):895–902.


73. Keller CA, Shepard JW Jr, Chun DS, et al., Pulmonary hypertension in chronic obstructive pulmonary disease: multivariate analysis, Chest, 1986;90(2):185–92.


74. Weitzenblum E, Sautegeau A, Ehrhart M, et al., Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease, Am Rev Resp Dis, 1984;130(6):993–8.


75. Nocturnal Oxygen Therapy Trial Group, Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease: a clinical trial, Ann Intern Med, 1980;93(3): 391–8.


76. Gerardi DA, Lovett L, Benoit-Connors ML, et al., Variables related to increased mortality following out-patient pulmonary rehabilitation, Eur Respir J, 1996;9(3):431–5.


77. Nishimura K, Izumi T, Tsukino M, Oga T, Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD, Chest, 2002;121(5):1434–40.


78. Schols AM, Slangen J, Volovics L, Wouters EF, Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 1998;157(6): 1791–7.


79. Soler-Cataluña JJ, Martinez-García MA, Román Sánchez P, et al., Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease, Thorax, 2005;60(11):925–31.


80. Celli BR, Cote CG, Marin JM, et al., The body mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease, N Engl J Med, 2004;350(10):1005–12.


US RESPIRATORY DISEASE


13


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84